Thermo Fisher Scientific and Mainz Biomed Partner to Advance Colorectal Cancer Screening
TL;DR
Early detection screening tool ColoAlert by Mainz Biomed has sensitivities exceeding 90% for detecting colorectal cancer, giving a competitive advantage in early intervention.
ColoAlert via stool samples spots four tumor markers associated with cancer, focusing on precancerous lesions and advanced adenomas, making the method of detection highly accurate.
Colorectal cancer is a major cause of death in America, killing 50,000 people each year, but early detection with ColoAlert can increase the survival rate to 90% after five years, making a better tomorrow.
Mainz Biomed's ColoAlert is easy to use, requires small samples, and provides results in a few days, making it a convenient and efficient way to detect colorectal cancer.
Found this article helpful?
Share it with your network and spread the knowledge!
In a significant development for colorectal cancer screening, Thermo Fisher Scientific Inc. (NYSE: TMO) and Mainz Biomed NV (NASDAQ: MYNZ) have announced a partnership to jointly develop and potentially commercialize ColoAlert, an innovative early detection screening test. This collaboration comes at a critical time as colorectal cancer cases among young people have increased dramatically over the past two decades, with a 500% rise in cases among youth and a 333% increase in children aged 10 to 14.
Colorectal cancer remains a major health concern in the United States, claiming approximately 50,000 lives annually. Despite the high survival rate of 90% when detected early, only about 40% of colorectal cancers are identified at this crucial stage. The partnership between Thermo Fisher Scientific and Mainz Biomed aims to address this issue by leveraging Thermo Fisher's advanced technologies and Mainz Biomed's expertise in molecular genetics diagnostics.
ColoAlert, Mainz Biomed's flagship product, is a non-invasive screening test that detects both bleeding and non-bleeding tumors through tumor DNA analysis. The test examines stool samples for four tumor markers associated with cancer: KRAS-mutation, BRAF-mutation, total amount of human DNA, and occult blood. In clinical trials, ColoAlert has demonstrated impressive sensitivities, exceeding 90% for detecting colorectal cancer and over 80% for advanced adenomas.
The collaboration will utilize Thermo Fisher Scientific's technologies, instrumentation, and information translation systems to enhance Mainz Biomed's development of proprietary assays for its mRNA-based next-generation colorectal cancer screening tests. This partnership is expected to accelerate the availability of an innovative new test for colorectal cancer screening worldwide.
Guido Baechler, CEO of Mainz Biomed, expressed enthusiasm about the collaboration, stating that it will be instrumental in bringing to market a home collection colorectal screening tool with highly effective detection of adenomas. The partnership is set to enhance product development significantly, leveraging Thermo Fisher Scientific's expertise and scalable technologies.
The importance of this collaboration extends beyond the immediate benefits to the companies involved. With the alarming increase in colorectal cancer cases among younger populations, there is a growing need for accessible and accurate screening methods. While widespread colonoscopy screening may not be recommended for all young adults, awareness of symptoms and early detection through non-invasive methods like ColoAlert could play a crucial role in combating this form of cancer.
ColoAlert's ease of use is another factor that could drive its adoption. The test can be completed at home within five minutes, with patients receiving a kit in the mail containing instructions, a stool collector, and a shipping label to return the sample to a local lab for testing. Results are typically available within a few days, and the company reports a 98% patient satisfaction rate.
As Mainz Biomed prepares to launch a clinical FDA trial in the United States next year, the potential impact of this collaboration on public health is significant. If successful, ColoAlert could become available to millions of Americans at risk of colorectal cancer, potentially improving early detection rates and, consequently, survival outcomes.
This partnership between Thermo Fisher Scientific and Mainz Biomed represents a significant step forward in the fight against colorectal cancer. By combining their respective strengths in technology and diagnostics, these companies are poised to make a substantial impact on cancer screening and early detection, potentially saving countless lives in the process.
Curated from News Direct
